Role of the cellular microRNA, miR-155, in EBV type III latency signaling

细胞 microRNA miR-155 在 EBV III 型潜伏信号传导中的作用

基本信息

  • 批准号:
    8247164
  • 负责人:
  • 金额:
    $ 29.99万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-01 至 2014-04-30
  • 项目状态:
    已结题

项目摘要

The Epstein Barr virus (EBV) is an oncogenic herpesvirus that is intimately involved in a number of malignancies in humans. The genetic basis of EBV associated oncogenesis is the concerted action of EBV latency associated genes and varying cellular genetic alterations. In immuno-competent individuals only minimal EBV latency gene expression can be tolerated due to the immunogeneticity of several EBV encoded latency gene products. In AIDS patients, however, expression of the full repertoire of latency genes (referred to as type III latency) can sometimes be tolerated and expression of these genes provide many essential elements of tumor cell development. In this setting, fewer cellular genetic alterations are required to give rise to malignant cell populations and this probably partly explains the greatly increased susceptibility of AIDS patients to EBV associated non-Hodgkin's lymphomas. The cellular microRNA, miR-155, is one of the most highly implicated microRNAs in cancer. miR-155 is induced by the EBV type III latency program (but not the type I latency program) suggesting a possible role for miR-155 in modulating type III latency signal transduction. Further evidence that miR-155 signaling is relevant to herpesvirus biology has been provided by Rolf Renne's lab and by Bryan Cullen's lab who both showed recently that the Kaposi's Sarcoma Herpes virus (KSHV) encodes a functional homologue of miR- 155. Two mouse miR-155 knock out papers recently showed that miR-155 is important for B cell activation responses following immune challenge. We hypothesize that induction of miR-155 by EBV type III latency plays a role in facilitating EBV mediated B cell activation and that miR-155 modulates signal transduction pathways that contribute to EBV associated maligancies in AIDS patients.
爱泼斯坦巴尔病毒(EBV)是一种致癌疱疹病毒,其密切参与许多免疫缺陷病毒。 人类的恶性肿瘤EBV相关肿瘤发生的遗传基础是EBV的协同作用 潜伏相关基因和不同的细胞遗传改变。仅免疫功能正常的个体 最小的EBV潜伏基因表达是可以容忍的,这是由于几种EBV编码的免疫原性。 潜伏基因产物然而,在艾滋病患者中,所有潜伏基因的表达(参考文献) 到III型潜伏期)有时是可以耐受的,这些基因的表达提供了许多必要的 肿瘤细胞发展的要素。在这种情况下,需要更少的细胞遗传改变来产生 恶性细胞群,这可能部分解释了艾滋病的易感性大大增加, EBV相关非霍奇金淋巴瘤的患者。 细胞microRNA,miR-155,是与癌症关系最密切的microRNA之一。miR-155是 由EB病毒III型潜伏期程序(但不是I型潜伏期程序)诱导,表明可能的作用 用于miR-155调节III型潜伏期信号转导。进一步的证据表明,miR-155信号是 与疱疹病毒生物学相关的研究由Rolf Renne的实验室和Bryan Cullen的实验室提供, 最近显示,卡波西肉瘤疱疹病毒(KSHV)编码miR-11的功能同源物, 155.最近两篇小鼠miR-155敲除论文表明miR-155对B细胞活化很重要 免疫攻击后的反应。我们假设,通过EB病毒III型潜伏期诱导miR-155表达, miR-155在促进EBV介导的B细胞活化中起作用,并且miR-155调节信号转导 导致艾滋病患者中EB病毒相关恶性肿瘤的途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ERIK K FLEMINGTON其他文献

ERIK K FLEMINGTON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ERIK K FLEMINGTON', 18)}}的其他基金

EBV reactivation causes widespread host de novo promoter transcription and transcriptional interference
EBV 重新激活导致广泛的宿主从头启动子转录和转录干扰
  • 批准号:
    10647826
  • 财政年份:
    2022
  • 资助金额:
    $ 29.99万
  • 项目类别:
EBV reactivation causes widespread host de novo promoter transcription and transcriptional interference
EBV 重新激活导致广泛的宿主从头启动子转录和转录干扰
  • 批准号:
    10548370
  • 财政年份:
    2022
  • 资助金额:
    $ 29.99万
  • 项目类别:
Programmed splicing derangement as new EBV host cell shut-off mechanism
程序性剪接紊乱作为新的 EBV 宿主细胞关闭机制
  • 批准号:
    10580068
  • 财政年份:
    2022
  • 资助金额:
    $ 29.99万
  • 项目类别:
Programmed splicing derangement as new EBV host cell shut-off mechanism
程序性剪接紊乱作为新的 EBV 宿主细胞关闭机制
  • 批准号:
    10446536
  • 财政年份:
    2022
  • 资助金额:
    $ 29.99万
  • 项目类别:
RPMS1 circular RNAs in EBV malignancies
EBV 恶性肿瘤中的 RPMS1 环状 RNA
  • 批准号:
    10397562
  • 财政年份:
    2019
  • 资助金额:
    $ 29.99万
  • 项目类别:
RPMS1 circular RNAs in EBV malignancies
EBV 恶性肿瘤中的 RPMS1 环状 RNA
  • 批准号:
    10612751
  • 财政年份:
    2019
  • 资助金额:
    $ 29.99万
  • 项目类别:
RPMS1 circular RNAs in EBV malignancies
EBV 恶性肿瘤中的 RPMS1 环状 RNA
  • 批准号:
    10153734
  • 财政年份:
    2019
  • 资助金额:
    $ 29.99万
  • 项目类别:
Project 2: Joint Transcriptomic and Epigenomic Studies for Male Osteoporosis
项目2:男性骨质疏松症的转录组和表观基因组联合研究
  • 批准号:
    10180819
  • 财政年份:
    2017
  • 资助金额:
    $ 29.99万
  • 项目类别:
"Core B" Viral RNA-seq and bioinformatics Core
“核心 B”病毒 RNA-seq 和生物信息学核心
  • 批准号:
    10403019
  • 财政年份:
    2017
  • 资助金额:
    $ 29.99万
  • 项目类别:
"Core B" Viral RNA-seq and bioinformatics Core
“核心 B”病毒 RNA-seq 和生物信息学核心
  • 批准号:
    10646252
  • 财政年份:
    2017
  • 资助金额:
    $ 29.99万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 29.99万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 29.99万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.99万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了